|Sponsor||Rep. Roe, Phil|
|Committee||Energy and Commerce|
|Date||July 30, 2013 (113th Congress, 1st Session)|
|Staff Contact||David Smentek|
On Tuesday, July 30, 2013, the House will consider H.R. 2094, the School Access to Emergency Epinephrine Act,under a suspension of the rules. The bill was introduced on May 22, 2013 by Rep. David Roe (R-TN) and referred to the Committee on Energy and Commerce, which ordered the bill reported by unanimous consent.
H.R. 2094 amends the Children’s Asthma Treatment Grants Program and other asthma programs administered by the Department of Health and Human Services (HHS) in order to encourage schools to plan for severe allergic reactions. The bill authorizes the Secretary to give funding preference to states for asthma-treatment grants if they meet the following requirements:
Additionally, states would have to certify that their laws provide civil liability protection for those who administer epinephrine.
There are nearly 6 million children in the United States who have food allergies. Anaphylaxis, a serious form of allergic reaction, is potentially fatal. In the case of an allergic reaction to food, epinephrine can be used to stop deadly swelling of the throat and tongue that occurs in an anaphylactic reaction. It also can help maintain normal blood pressure for someone suffering from an allergic reaction. However, in the case of an emergency, epinephrine is needed in a short period of time. Considering that a quarter of anaphylaxis cases in U.S. schools happen without previous knowledge of a food allergy, an emergency supply of epinephrine can potentially save lives.
According to the CBO, the bill would have no effect on direct spending or revenues. There is no new spending in the bill, and thus the CBO expects the bill to have no significant impact on the federal budget.
For questions or further information contact the GOP Conference at 5-5107.